Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Investing Activities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Cash from Investing Activities data on record, last reported at $9.1 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 130.31% year-over-year to $9.1 million; the TTM value through Sep 2025 reached -$124.9 million, down 33.58%, while the annual FY2024 figure was -$107.5 million, 201.44% down from the prior year.
  • Cash from Investing Activities reached $9.1 million in Q3 2025 per STOK's latest filing, up from -$148.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $67.3 million in Q3 2022 and bottomed at -$148.5 million in Q2 2025.
  • Average Cash from Investing Activities over 4 years is -$11.5 million, with a median of $10.0 million recorded in 2024.
  • Peak YoY movement for Cash from Investing Activities: surged 15977.4% in 2023, then crashed 476.08% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at $22.5 million in 2022, then crashed by 34.32% to $14.8 million in 2023, then plummeted by 94.46% to $819000.0 in 2024, then surged by 1010.38% to $9.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $9.1 million in Q3 2025, -$148.5 million in Q2 2025, and $13.6 million in Q1 2025.